Tag:
hepatitis B
Latest Headlines
Latest Headlines
Press Release: Coley Pharmaceutical Group Grants Dynavax License for Commercialization of Heplisav
Press Release: Coley Pharmaceutical Group Grants Dynavax License for Commercialization of Heplisav
Anacor forges $625M pact with Schering-Plough
Anacor Pharmaceuticals will pocket an initial $50 million and up to $575 million in milestones in a licensing deal with Schering-Plough involving an experimental fungal therapy. Palo Alto, CA-based Anacor gets a $40 million upfront fee and a $10 million financing commitment for the pact regarding AN2690. Schering-Plough takes over the development of the drug, now in Phase II, while Anacor retains the right to co-promote the therapy in the U.S. to dermatologists. "The co-promote …
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Schering-Plough licenses hepatitis B drug
Shares of Valeant Pharmaceuticals and Metabasis Technologies jumped late Wednesday after they announced that Schering-Plough had licensed the experimental pradefovir for chronic hepatitis B. Valeant licensed the drug from Metabasis six years ago. Both companies will earn an up-front payment along with a schedule of milestones. "Pradefovir has the potential to offer improved treatment options for patients with chronic hepatitis B, a serious blood-borne infection affecting some 400 …
Press Release: Positive Results for Liver Cancer Trial
Press Release: Positive Results for Liver Cancer Trial
Dynavax stock jumps on hep B data
Shares of Dynavax Technologies shot up 31 percent in after-hours trading after the developer announced that a late-stage trial of its experimental vaccine for hepatitis B showed that it performed better after two doses than three doses of GlaxoSmithKline's vaccine. Two doses of Hepislav protected 98 percent of volunteers compared to 25 percent protected by two doses of Glaxo's Engerix-B. Analysts say the data shows that Dynavax can successfully compete against Glaxo in the $1 billion …
FDA approves hepatitis B drug
The FDA has approved Tyzeka for hepatitis B, a drug developed by Idenix and Novartis. Tyzeka is expected to treat symptoms of the disease. It joins six other meds approved for HBV.- here's the report on Tyzeka from EarthTimes
ALSO NOTED: Nucryst drug fails trial; Dr. Bugg to retire from Biocryst; Pozen shares jump; and much more...
> Nucryst Pharmaceuticals announced that a mid-stage trial of its topical cream for dermatitis did not achieve its goal, according to a preliminary review of the data. The company plans to continue to study other uses of the drug. Report > Chutes & Ladders: BioCryst Pharmaceuticals announced that Charles E. Bugg, Ph.D., the company's chairman, CEO and co-founder, has informed …
FDA panel votes in favor of Nabi therapy
In a lopsided 9-2 vote, an FDA expert panel on blood products has concluded that Nabi Biopharmaceuticals hepatitis B therapy should be approved as a therapy to prevent the recurrence of hepatitis B in liver transplant patients. The agency originally approved Nabi-HB seven years ago to prevent the disease after exposure. The panel came to a different conclusion than the agency's staff, which said that Nabi had not sufficiently demonstrated the efficacy of the drug in transplants. One …
Pharmasset files for $75M IPO
Pharmasset has filed an IPO to raise up to $75 million. The Princeton, NJ-based drug developer has candidates for HIV, hepatitis B and hepatitis C in clinical development. Pharmasset had $832,751 in revenue for the quarter ended December 31. As is usual in these cases, the company did not file any details about the number of shares to be offered or the price at which they would be offered.- here's the report from the Seattle Post-Intelligencer
